ROIV
Roivant Sciences is a biopharmaceutical company developing a diversified pipeline of small molecule inhibitors, monoclonal antibodies, and inhaled activators across immunology and rare disease indications. Lead programs include brepocitinib, a TYK2 and JAK1 inhibitor in Phase 3 development for dermatomyositis and non-infectious uveitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in Phase 2/3 and Phase 3 development respectively across multiple IgG-mediated autoimmune conditions including Graves disease, myasthenia gravis, and thyroid eye disease; and mosliciguat, an inhaled sGC activator in Phase 2 development for pulmonary hypertension associated with interstitial lung disease. Roivant operates through subsidiary
Pipeline
Catalyst Calendar
“the elimination of fixed quarterly payments totaling $176.3 million that would have been due and payable following regulatory approval of tapinarof in the U.S. for atopic dermatitis, if approved”
“a $75 million milestone payment payable upon FDA approval of VTAMA® (the "Product") for the treatment of atopic dermatitis”
“topline results from Kinevant's Phase 2 RESOLVE-Lung study of namilumab in chronic active pulmonary sarcoidosis”
“topline results from Immunovant's two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease”
“a new Phase 2b/3 clinical program at Priovant for brepocitinib in lichen planopilaris”